메뉴 건너뛰기




Volumn 156, Issue 1, 2008, Pages 135-140

One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; TROPONIN T;

EID: 45649083470     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.006     Document Type: Article
Times cited : (47)

References (27)
  • 1
    • 0036067568 scopus 로고    scopus 로고
    • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    • Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 113 (2002) 1-6
    • (2002) Am J Med , vol.113 , pp. 1-6
    • Topol, E.J.1    Lincoff, A.M.2    Kereiakes, D.J.3
  • 2
    • 2242477091 scopus 로고
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330 (1994) 956-961
    • (1994) N Engl J Med , vol.330 , pp. 956-961
  • 3
    • 33845709129 scopus 로고    scopus 로고
    • A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation
    • Bertrand O.F., De Larochelliere R., Rodes-Cabau J., et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114 (2006) 2636-2643
    • (2006) Circulation , vol.114 , pp. 2636-2643
    • Bertrand, O.F.1    De Larochelliere, R.2    Rodes-Cabau, J.3
  • 4
    • 0035195534 scopus 로고    scopus 로고
    • American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)
    • Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38 (2001) 2114-2130
    • (2001) J Am Coll Cardiol , vol.38 , pp. 2114-2130
    • Cannon, C.P.1    Battler, A.2    Brindis, R.G.3
  • 5
    • 33645507439 scopus 로고    scopus 로고
    • Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial
    • Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Jama 295 (2006) 1531-1538
    • (2006) Jama , vol.295 , pp. 1531-1538
    • Kastrati, A.1    Mehilli, J.2    Neumann, F.J.3
  • 6
    • 9144228045 scopus 로고    scopus 로고
    • A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel
    • Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
    • (2004) N Engl J Med , vol.350 , pp. 232-238
    • Kastrati, A.1    Mehilli, J.2    Schuhlen, H.3
  • 7
    • 0028117857 scopus 로고
    • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
    • Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
    • (1994) Circulation , vol.90 , pp. 1757-1764
    • Tcheng, J.E.1    Ellis, S.G.2    George, B.S.3
  • 8
    • 33749331837 scopus 로고    scopus 로고
    • High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions
    • Fischell T.A., Attia T., Rane S., et al. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 18 (2006) 487-491
    • (2006) J Invasive Cardiol , vol.18 , pp. 487-491
    • Fischell, T.A.1    Attia, T.2    Rane, S.3
  • 9
    • 33750700519 scopus 로고    scopus 로고
    • Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention
    • Marmur J.D., Poludasu S., Agarwal A., et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 18 (2006) 521-526
    • (2006) J Invasive Cardiol , vol.18 , pp. 521-526
    • Marmur, J.D.1    Poludasu, S.2    Agarwal, A.3
  • 10
    • 33750300540 scopus 로고    scopus 로고
    • Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial
    • Marmur J.D., Mitre C.A., Barnathan E., et al. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am Heart J 152 (2006) 876-881
    • (2006) Am Heart J , vol.152 , pp. 876-881
    • Marmur, J.D.1    Mitre, C.A.2    Barnathan, E.3
  • 11
    • 0037145863 scopus 로고    scopus 로고
    • Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    • Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3
  • 12
    • 9644291514 scopus 로고    scopus 로고
    • Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    • Kandzari D.E., Berger P.B., Kastrati A., et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44 (2004) 2133-2136
    • (2004) J Am Coll Cardiol , vol.44 , pp. 2133-2136
    • Kandzari, D.E.1    Berger, P.B.2    Kastrati, A.3
  • 13
    • 4944261759 scopus 로고    scopus 로고
    • Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy
    • Kastrati A., von Beckerath N., Joost A., et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
    • (2004) Circulation , vol.110 , pp. 1916-1919
    • Kastrati, A.1    von Beckerath, N.2    Joost, A.3
  • 14
    • 33644587565 scopus 로고    scopus 로고
    • Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
    • Steinhubl S.R., Berger P.B., Brennan D.M., et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 47 (2006) 939-943
    • (2006) J Am Coll Cardiol , vol.47 , pp. 939-943
    • Steinhubl, S.R.1    Berger, P.B.2    Brennan, D.M.3
  • 15
    • 0035887138 scopus 로고    scopus 로고
    • Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-6, A6.
    • Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-6, A6.
  • 16
    • 0037151685 scopus 로고    scopus 로고
    • Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)
    • Bonz A.W., Lengenfelder B., Strotmann J., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 40 (2002) 662-668
    • (2002) J Am Coll Cardiol , vol.40 , pp. 662-668
    • Bonz, A.W.1    Lengenfelder, B.2    Strotmann, J.3
  • 17
    • 3242785367 scopus 로고    scopus 로고
    • Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET)
    • Chan A.W., Moliterno D.J., Berger P.B., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
    • (2003) J Am Coll Cardiol , vol.42 , pp. 1188-1195
    • Chan, A.W.1    Moliterno, D.J.2    Berger, P.B.3
  • 18
    • 14944378655 scopus 로고    scopus 로고
    • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
    • Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
    • (2005) Circulation , vol.111 , pp. 1153-1159
    • Gurbel, P.A.1    Bliden, K.P.2    Zaman, K.A.3
  • 19
    • 33645052218 scopus 로고    scopus 로고
    • ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)
    • Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
    • (2006) Circulation , vol.113
    • Smith Jr., S.C.1    Feldman, T.E.2    Hirshfeld Jr., J.W.3
  • 20
    • 19244387281 scopus 로고    scopus 로고
    • Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
    • Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35 (2000) 915-921
    • (2000) J Am Coll Cardiol , vol.35 , pp. 915-921
    • Neumann, F.J.1    Kastrati, A.2    Schmitt, C.3
  • 21
    • 0028345255 scopus 로고
    • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators
    • Topol E.J., Califf R.M., Weisman H.F., et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343 (1994) 881-886
    • (1994) Lancet , vol.343 , pp. 881-886
    • Topol, E.J.1    Califf, R.M.2    Weisman, H.F.3
  • 22
    • 20244385431 scopus 로고    scopus 로고
    • Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
    • Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37 (2001) 2059-2065
    • (2001) J Am Coll Cardiol , vol.37 , pp. 2059-2065
    • Anderson, K.M.1    Califf, R.M.2    Stone, G.W.3
  • 23
    • 3843060250 scopus 로고    scopus 로고
    • Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
    • Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. Jama 292 (2004) 696-703
    • (2004) Jama , vol.292 , pp. 696-703
    • Lincoff, A.M.1    Kleiman, N.S.2    Kereiakes, D.J.3
  • 24
    • 27944459673 scopus 로고    scopus 로고
    • Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
    • Mukherjee D., Topol E.J., Bertrand M.E., et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 26 (2005) 2524-2528
    • (2005) Eur Heart J , vol.26 , pp. 2524-2528
    • Mukherjee, D.1    Topol, E.J.2    Bertrand, M.E.3
  • 25
    • 33947575142 scopus 로고    scopus 로고
    • Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial
    • Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1362-1368
    • Manoukian, S.V.1    Feit, F.2    Mehran, R.3
  • 26
    • 33947187284 scopus 로고    scopus 로고
    • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    • Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
    • (2007) Lancet , vol.369 , pp. 907-919
    • Stone, G.W.1    White, H.D.2    Ohman, E.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.